When most of a company's eggs are in one basket, it's entirely reasonable to want to sell your shares if you find out there's a big hole in the bottom.
Such is the case with CureVac (NASDAQ: CVAC) in light of its most recent coronavirus vaccine trial. The latest data readout from the trial was a total catastrophe, and the stock plummeted as a result. The company probably isn't finished, but investors should probably steer clear for the foreseeable future -- unless they're interested in taking a risk by bucking the trend, that is.
Image source: Getty Images.
For further details see:
Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?